Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine

Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift toward higher-margin products and expanding global distribution. Q2 2026 results showed broad-based revenue growth (9% YoY), significant margin expansion, and strong operating cash flow, supporting an optimistic outlook. Premium intraocular lenses and branded pharmaceuticals are driving faster growth, improving mix, and enabling margin and EBITDA expansion without unsustainable revenue acceleration. Despite $5.1B in debt and a parent overhang, BLCO trades at a steep valuation discount; continued execution and deleveraging could catalyze multiple re-ratings.

I am optimistic about the future performance of Bausch + Lomb (BLCO), based primarily on the expectation that investors will continue to view the company as a leveraged collection of mature eye care products.